Meta-Analysis: How Well Do Dual and Triple Incretin Agonists Work for Weight Loss? | Research

The takeaway

A systematic review and meta-analysis evaluates the efficacy and safety of dual and triple incretin agonists for obesity, finding enhanced weight loss through multi-receptor targeting.

Dual + triple agonists analyzed
First comprehensive meta-analysis pooling RCT data on multi-receptor incretin drugs for obesity

What the researchers found

Incretin-based dual and triple agonists demonstrate enhanced weight loss compared to single-receptor approaches, with the meta-analysis quantifying efficacy and safety across available RCTs.

Why it matters

Dual and triple agonists represent the next generation of obesity drugs. This meta-analysis provides the first comprehensive pooled evidence on whether targeting more receptors truly translates to better weight loss outcomes.

How the study worked

Systematic review and meta-analysis of RCTs from PubMed, Cochrane Library, and Google Scholar through June 2025.

What this study cannot tell us

Limited number of available trials for triple agonists; heterogeneity in study designs and populations; most triple-agonist data from early-phase trials.

How to read the evidence

Systematic review and meta-analysis of RCTs — highest level of evidence synthesis, though limited by available primary study data.

When this study was published

Published in 2026 with literature through June 2025, capturing the most current trial data on emerging multi-agonist drugs.

The bigger picture

The obesity pharmacotherapy landscape is rapidly evolving from single-target to multi-target approaches. This analysis helps define how much additional benefit each added receptor target provides.

Questions still open

Do triple agonists provide meaningfully better weight loss than dual agonists to justify potential additional risks?
Which patient populations benefit most from multi-receptor versus single-receptor agonism?

Common questions

What are dual and triple incretin agonists?

Dual agonists (like tirzepatide) activate two hormone receptors (GLP-1 and GIP), while triple agonists add a third target (glucagon receptor). More targets may produce greater weight loss but could also increase side effects.

Are triple agonists better than dual agonists for weight loss?

This meta-analysis examines that question by pooling all available trial data. While multi-receptor targeting shows enhanced efficacy, the optimal balance of benefits and risks is still being determined.

Read the original research

Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.

Cardiology in review

View on PubMed ↗Publisher’s paper ↗

Citation

Chan, Zhi Hong; Omar, Abdousamad Said; Gill, Kieran; Volucke, Gabriele; Azhar, Muhammad Muneeb; Haleem, Syed Mohammad; Sia, Jian En; Rahman, Obaid Ur; Ahmad, Moaz; Shahid, Nuraan; Gardezi, Syed Anjum; Joseph, Kevin Vinod; Behary Paray, Nitish; Zulfiqar, Eeshal. (2026). Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.. Cardiology in review. https://doi.org/10.1097/CRD.0000000000001209